Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Experimental and Therapeutic Medicine

Volumn 9, Issue 3, 2015, Pages 1006-1012

  Ma, Teng ^a   Xu, Jiacheng ^a   Zhuang, Jiawei ^a   Zhou, Xiaobiao ^a   Lin, Lianfeng ^a   Shan, Zhonggui ^a   Qi, Zhongquan ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b Organ Transplantation Institute Medical College iamen University   (China)

Author keywords

C X C motif chemokine 10; C X C motif chemokine 9; Cardiac retransplantation; Chemokines; FTY720

Indexed keywords

ANTIBODY; COMPLEMENTARY DNA; CXCL9 CHEMOKINE ANTIBODY; FINGOLIMOD; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRDU ASSAY; CARDIAC GRAFT REJECTION; CARDIAC RETRANSPLANTATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HEART MUSCLE NECROSIS; HISTOLOGY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LYMPHOCYTE PROLIFERATION; MICROVASCULAR SURGERY; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; ORGAN DONOR; RETRANSPLANTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; SKIN TRANSPLANTATION; SURVIVAL TIME; T LYMPHOCYTE; UPREGULATION;

EID: 84922022057     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2204     Document Type: Article

References (28)

1. Taylor DO, Edwards LB, et al: Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report - 2006. J Heart Lung Transplant 25: 869-879, 2006.
2. Pour-Reza-Gholi F, Nafar M, Saeedinia A, Farrokhi F, Firouzan A, Simforoosh N, Basiri A and Einollahi B: Kidney retransplantation in comparison with first kidney transplantation. Transplant Proc 37: 2962-2964, 2005.
3. Amir AL, D'Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, van der Hoorn MA, Kester MG, Doxiadis II, Falkenburg JH et al: Allo-HLA reactivity of virus-specific memory T cells is common. Blood 115: 3146-3157, 2010.
4. Bingaman AW and Farber DL: Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant 4: 846-852, 2004.
5. Valujskikh A and Li XC: Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol 18: 2252-2261, 2007.
6. Yun JJ, Whiting D, Fischbein MP, Banerji A, Irie Y, Stein D, Fishbein MC, Proudfoot AE, Laks H, Berliner JA and Ardehali A: Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 109: 932-937, 2004.
7. Iida S, Suzuki T, Tanabe K, Valujskikh A, Fairchild RL and Abe R: Transient lymphopenia breaks costimulatory blockade-based peripheral tolerance and initiates cardiac allograft rejection. Am J Transplant 13: 2268-2279, 2013
8. Wang H, Zhang Z, Tian W, Liu T, Han H, Garcia B, Li XC and Du C: Memory T cells mediate cardiac allograft vasculopathy and are inactivated by anti-OX40L monoclonal antibody. Cardiovasc Drugs Ther 28: 115-122, 2014.
9. Liang H, Liao C, Qi Z, Sha C, Xie B, Chen J, Xia J, Wang Y, Yao Q and Zhao Y: Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4(+) memory T cells in mice. Transpl Immunol 22: 128-136, 2010.
10. Larsen CP, Knechtle SJ, Adams A, Pearson T and Kirk AD: A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 6: 876-883, 2006.
11. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S and Lanzavecchia A: Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 28: 2760-2769, 1998.
12. Zhai Y, Wang Y, Wu Z and Kupiec-Weglinski JW: Defective alloreactive CD8 T cell function and memory response in allograft recipients in the absence of CD4 help. J Immunol 179: 4529-4534, 2007.
13. Rosenblum JM, Shimoda N, Schenk AD, Zhang H, Kish DD, Keslar K, Farber JM and Fairchild RL: CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J Immunol 184: 3450-3460, 2010.
14. Zhou X, Shan Z, Liang H, et al: Role of regulated upon activation normal T-cell expressed and secreted in a model of retransplan- tation acute rejection mediated by alloreactive memory CD4+T cells. Transplant Proc 45: 546-551, 2013.
15. Chen ZH: A technique of cervical heterotopic heart transplantation in mice. Transplantation 52: 1099-1101, 1991.
16. Billingham ME, Cary NR, Hammond ME, et al: A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9: 587-593, 1990.
17. Winters GL, Marboe CC and Billingham ME: The International Society for Heart and Lung Transplantation grading system for heart transplant biopsy specimens: clarification and commentary. J Heart Lung Transplant 17: 754-760, 1998.
18. Salom RN, Maguire JA and Hancock WW: Endothelial activation and cytokine expression in human acute cardiac allograft rejection. Pathology. 30: 24-29, 1998.
19. Setoguchi K, Hattori Y, Iida S, Baldwin WM III and Fairchild RL: Endogenous memory CD8 T cells are activated within cardiac allografts without mediating rejection. Am J Transplant. 13: 2293-2307, 2013.
20. Farivar AS, Mackinnon-Patterson BC, McCourtie AS, Ward PA and Mulligan MS: The role of CC and CXC chemokines in cardiac allograft rejection in rats. Exp Mol Pathol 78: 171-176, 2005.
21. + T cells. Transplant Proc 45: 546-551, 2013.
22. Liu Y, Jiang J, Xiao H, Wang X, et al: Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice. Mol Vis 18: 624-633, 2012.
23. Heng Y, Ma Y, Yin H, Duan L, et al: Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival. Transpl Int 23: 1259-1270, 2010.
24. Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, Swanson SJ, Mannon RB, Roederer M and Kirk AD.: Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5: 465-474, 2005.
25. Zhang L, Zhu T, Sun EW, Shen SQ, Min ZL and Chen ZK: Pretreatment with FTY720 alone induced long-term survival of mouse heart allograft. Transplant Proc 35: 567-568, 2003.
26. Wang ME, Tejpal N, Qu X, Yu J, Okamoto M, Stepkowski SM and Kahan BD: Immunosuppressive effects of FTY720 alone or in combination with cyclosporine and/or sirolimus. Transplantation 65: 899-905, 1998.
27. Yanagawa Y, Hoshino Y and Chiba K: The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival. Int J Immunopharmacol 22: 597-602, 2000.
28. Kim MG, Lee SY, Ko YS, Lee HY, Jo SK, Cho WY and Kim HK: CD4+ CD25+ regulatory T cells partially mediate the beneficial effects of FTY720, a sphingosine-1-phosphate analogue, during ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant. 26: 111-24, 2011.